MCID: HMG003
MIFTS: 44

Hemoglobin E Disease malady

Categories: Rare diseases, Genetic diseases, Blood diseases

Aliases & Classifications for Hemoglobin E Disease

Aliases & Descriptions for Hemoglobin E Disease:

Name: Hemoglobin E Disease 12 50 56 14 69
Hemoglobin E 24 29
Hb-E Disease 12

Characteristics:

Orphanet epidemiological data:

56
hemoglobin e disease
Inheritance: Autosomal recessive; Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:5379
ICD10 33 D58.2
NCIt 47 C35287
SNOMED-CT 64 25065001
Orphanet 56 ORPHA2133
ICD10 via Orphanet 34 D58.2
UMLS via Orphanet 70 C0238159
UMLS 69 C0238159

Summaries for Hemoglobin E Disease

NIH Rare Diseases : 50 hemoglobin e (hbe) disease is a mild, inherited blood disorder characterized by an abnormal form of hemoglobin, called hemoglobin e. people with this condition may have very mild anemia, but the condition typically does not cause any symptoms. it is inherited in an autosomal recessive manner and is caused by a mutation in the hbb gene. the mutation that causes hemoglobin e disease primarily occurs in southeast asian populations, and rarely in chinese populations. most people with hbe disease do not need any treatment.  last updated: 3/22/2017

MalaCards based summary : Hemoglobin E Disease, also known as hemoglobin e, is related to hemoglobin e-beta-thalassemia syndrome and hemoglobin se disease. An important gene associated with Hemoglobin E Disease is HBB (Hemoglobin Subunit Beta), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Binding and Uptake of Ligands by Scavenger Receptors. The drugs Glyburide and Zinc have been mentioned in the context of this disorder. Affiliated tissues include liver and colon.

Related Diseases for Hemoglobin E Disease

Diseases in the Hemoglobin Sd family:

Hemoglobin C Disease Hemoglobin D Disease
Hemoglobin E Disease Hemoglobin Se Disease
Hemoglobin So

Diseases related to Hemoglobin E Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
id Related Disease Score Top Affiliating Genes
1 hemoglobin e-beta-thalassemia syndrome 11.9
2 hemoglobin se disease 11.2
3 thalassemia 10.3
4 landau-kleffner syndrome 10.2 F2 HBB
5 chronic inflammatory demyelinating polyneuritis 10.2 F2 HBB
6 michelin tire baby syndrome 10.2 HBA1 HBB
7 surfactant metabolism dysfunction, pulmonary, 3 10.2 HBA1 HBB
8 chronic laryngitis 10.2 HBA1 HBB
9 congenital insensitivity to pain with severe intellectual disability 10.2 F2 F5
10 vascular erectile tumor 10.2 F2 F5
11 hemopneumothorax 10.2 F2 HBA1
12 lubinsky syndrome 10.2 F2 F5
13 supraumbilical midabdominal raphe and facial cavernous hemangiomas 10.2 F2 F5
14 pancreatic ductal carcinoma 10.2 F2 F5
15 hendra virus infection 10.2 F2 F5
16 stroke, ischemic 10.2 F2 F5
17 left-right axis malformations 10.2 F2 F5
18 lymphocytic colitis 10.2 F2 F5
19 photosensitive epilepsy 10.2 F2 F5
20 bullous skin disease 10.1 F2 F5
21 fletcher factor deficiency 10.1 F2 F5
22 neuroaxonal dystrophy 10.1 F2 F5
23 cerebellar astrocytoma 10.1 F2 HBA1
24 lynch syndrome 10.1 F2 F5
25 myotonic dystrophy 10.1 F2 F5
26 cryptosporidiosis 10.1 F2 F5
27 angular blepharoconjunctivitis 10.1 F2 F5
28 houlston ironton temple syndrome 10.1 F2 F5
29 eagle syndrome 10.1 F2 F5
30 blepharoconjunctivitis 10.1 F2 F5
31 intestinal disaccharidase deficiency 10.1 F2 F5
32 dysgammaglobulinemia 10.1 F2 F5
33 brachydactyly type a1d 10.1 HBB HBE1
34 villous adenoma 10.1 F2 F5
35 ophthalmia neonatorum 10.1 F2 F5
36 vaginal discharge 10.1 F2 F5
37 pregnancy loss, recurrent 2 10.1 F2 F5
38 larynx sarcoma 10.1 HBA1 HBB
39 invasive pneumococcal disease, recurrent isolated, 1 10.1 F2 F5
40 low anorectal malformation 10.1 F2 F5
41 otopalatodigital syndrome, type i 10.1 F2 F5
42 alcoholic gastritis 10.1 F2 F5
43 scar contracture 10.1 F2 F5
44 uterine corpus cancer 10.1 F2 F5
45 atrophic nonflaccid tympanic membrane 10.1 F2 F5
46 pregnancy loss, recurrent 1 10.1 F2 F5
47 oguchi disease-2 10.1 F2 F5
48 thrombophilia due to activated protein c resistance 10.1 F2 F5
49 aids dementia complex 10.1 F2 F5
50 brill-zinsser disease 10.1 F2 F5

Graphical network of the top 20 diseases related to Hemoglobin E Disease:



Diseases related to Hemoglobin E Disease

Symptoms & Phenotypes for Hemoglobin E Disease

Drugs & Therapeutics for Hemoglobin E Disease

Drugs for Hemoglobin E Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 559)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glyburide Approved Phase 4 10238-21-8 3488
2
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
3
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
4
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
5
Copper Approved Phase 4,Phase 2 15158-11-9, 7440-50-8 27099
6
Selenium Approved, Vet_approved Phase 4,Phase 2 7782-49-2
7
Hydroxocobalamin Approved Phase 4,Phase 2 13422-51-0 11953898 5460373 44475014
8
Darbepoetin alfa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11096-26-7, 209810-58-2
9
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
10
Norepinephrine Approved Phase 4 51-41-2 439260
11
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
12
Fenofibrate Approved Phase 4 49562-28-9 3339
13
Rosiglitazone Approved, Investigational Phase 4,Phase 3 122320-73-4 77999
14
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
15
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
16
Glimepiride Approved Phase 4,Phase 3,Phase 2 93479-97-1 3476
17
Hydroxyurea Approved Phase 4,Phase 2,Phase 1,Early Phase 1 127-07-1 3657
18
Ramipril Approved Phase 4 87333-19-5 5362129
19
Ribavirin Approved Phase 4,Phase 2 36791-04-5 37542
20
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
21
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
22
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
23
Tranexamic Acid Approved Phase 4 1197-18-8 5526
24
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
25
Saxagliptin Approved Phase 4,Phase 3 361442-04-8 11243969
26
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2
27
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
28
Empagliflozin Approved Phase 4,Phase 3 864070-44-0
29
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
30
Insulin Aspart Approved Phase 4,Phase 3,Phase 2 116094-23-6 16132418
31
Insulin Glargine Approved Phase 4,Phase 3,Phase 2 160337-95-1
32
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
33
Fluorouracil Approved Phase 4,Phase 1,Phase 2 51-21-8 3385
34
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
35
Lumefantrine Approved Phase 4,Phase 3,Phase 1 82186-77-4 6437380
36
Artemether Approved Phase 4,Phase 3,Phase 1 71963-77-4 119380 68911
37
Insulin Lispro Approved Phase 4 133107-64-9
38
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
39
Desogestrel Approved Phase 4 54024-22-5 40973
40
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
41
Gliclazide Approved Phase 4 21187-98-4 3475
42
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
43
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
44
Insulin-glulisine Approved Phase 4 207748-29-6
45
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 65-23-6 1054
46
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 59-67-6 938
47
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 11103-57-4, 68-26-8 445354
48
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
49
Riboflavin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 83-88-5 493570
50
Vitamin C Approved, Nutraceutical Phase 4,Phase 2,Phase 3 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 501)
id Name Status NCT ID Phase
1 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4
2 Glargine Versus NPH in Patients With Chronic Kidney Disease Completed NCT02451917 Phase 4
3 A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease Completed NCT01132690 Phase 4
4 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4
5 Comparison Among Erythropoietin Stimulating Agents Completed NCT02049346 Phase 4
6 A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia Completed NCT00642668 Phase 4
7 Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD) Completed NCT02232906 Phase 4
8 Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone. Completed NCT00449553 Phase 4
9 Effect of Prenatal Nutritional Supplementation on Birth Outcome in Hounde District, Burkina Faso Completed NCT00909974 Phase 4
10 Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects Completed NCT02705807 Phase 4
11 A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia Completed NCT01342640 Phase 4
12 Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery Completed NCT01174719 Phase 4
13 Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso Completed NCT00642408 Phase 4
14 A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®) Completed NCT01256658 Phase 4
15 Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure Completed NCT01117350 Phase 4
16 Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes Completed NCT00470158 Phase 4
17 Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia Completed NCT01374373 Phase 4
18 TissueLink Study During Multi-Level Spine Surgery Completed NCT01300559 Phase 4
19 Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet Completed NCT00118937 Phase 4
20 Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin. Completed NCT02157298 Phase 4
21 A Study for Type 2 Diabetic Patients Completed NCT00548808 Phase 4
22 Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty Completed NCT01410240 Phase 4
23 Lantus in the Treatment of Type 1 Diabetes Children Completed NCT00206401 Phase 4
24 Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus Completed NCT00502242 Phase 4
25 Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus. Completed NCT00770835 Phase 4
26 Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age Completed NCT01110356 Phase 4
27 Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus. Completed NCT00770445 Phase 4
28 Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia Completed NCT00304993 Phase 4
29 Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section Completed NCT02739815 Phase 4
30 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
31 Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes Completed NCT01223196 Phase 4
32 Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet Completed NCT00118950 Phase 4
33 PVP Compared to TURP for the Treatment of Benign Hyperplasia of the Prostate Completed NCT00527371 Phase 4
34 A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy Recruiting NCT01191983 Phase 4
35 Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients Recruiting NCT02198495 Phase 4
36 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Recruiting NCT02774057 Phase 4
37 Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study Recruiting NCT02155439 Phase 4
38 Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial Recruiting NCT02330406 Phase 4
39 Ramipril Treatment of Claudication Recruiting NCT02842424 Phase 4
40 Mortality Reduction After Oral Azithromycin: Morbidity Study Recruiting NCT02048007 Phase 4
41 Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection. Recruiting NCT02558114 Phase 4
42 Oral Contraceptive Therapy and Sexuality Recruiting NCT02613039 Phase 4
43 Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes Recruiting NCT02407899 Phase 4
44 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Recruiting NCT02249897 Phase 4
45 Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality Recruiting NCT03036462 Phase 4
46 Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes Recruiting NCT02617693 Phase 4
47 Aspiration Therapy in Asian Patients Recruiting NCT02881684 Phase 4
48 A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria Recruiting NCT03118713 Phase 4
49 Empagliflozin in Renal Transplant Recipients Recruiting NCT03157414 Phase 4
50 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4

Search NIH Clinical Center for Hemoglobin E Disease

Genetic Tests for Hemoglobin E Disease

Genetic tests related to Hemoglobin E Disease:

id Genetic test Affiliating Genes
1 Hemoglobin E 29 24 HBB
2 Hemoglobin E Disease 29

Anatomical Context for Hemoglobin E Disease

MalaCards organs/tissues related to Hemoglobin E Disease:

39
Liver, Colon

Publications for Hemoglobin E Disease

Articles related to Hemoglobin E Disease:

(show all 35)
id Title Authors Year
1
Pregnancy Outcomes Among Women with Homozygous Hemoglobin E Disease: A Retrospective Cohort Study. ( 27456306 )
2016
2
Hemoglobin E disease and glycosylated hemoglobin. ( 26425484 )
2015
3
Detection of beta-thalassemia/hemoglobin E disease in samples which initially were diagnosed as homozygous hemoglobin E. ( 23865372 )
2013
4
Massive hemothorax due to intrathoracic extramedullary hematopoiesis in a patient with beta thalassemia hemoglobin E disease. ( 24319860 )
2013
5
Thrombotic thrombocytopenic purpura in a patient with hemoglobin E disease-the importance of timely examination of a blood film. ( 22473629 )
2012
6
Outcomes of pregnancies complicated by beta-thalassemia/hemoglobin E disease. ( 19084837 )
2009
7
Hemoglobin E disease with concomitant tuberculosis. ( 19008605 )
2008
8
Severe beta(0) thalassemia/hemoglobin E disease caused by de novo 22-base pair duplication in the paternal allele of beta globin gene. ( 17160997 )
2007
9
Hemostatic alterations in splenectomized and non-splenectomized patients with beta-thalassemia/hemoglobin E disease. ( 17382994 )
2007
10
Hemoglobin E disease in North Indian population: a report of 11 cases. ( 17654063 )
2007
11
Allogeneic peripheral blood stem cell transplantation in children with homozygous beta-thalassemia and severe beta-thalassemia/hemoglobin E disease. ( 15087953 )
2004
12
Hemin: a possible cause of oxidative stress in blood circulation of beta-thalassemia/hemoglobin E disease. ( 12653201 )
2003
13
Sickle cell-hemoglobin E disease in an Indian family. ( 12035368 )
2001
14
Clinical manifestation of beta-thalassemia/hemoglobin E disease. ( 11132229 )
2000
15
Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. ( 8562958 )
1996
16
Role of alternatively spliced beta E-globin mRNA on clinical severity of beta-thalassemia/hemoglobin E disease. ( 8629114 )
1995
17
Liver tissue injury secondary to iron overload in beta-thalassemia/hemoglobin E disease. ( 1298983 )
1992
18
Identification of five rare mutations including a novel frameshift mutation causing beta zero-thalassemia in Thai patients with beta zero-thalassemia/hemoglobin E disease. ( 1515453 )
1992
19
Increase in spontaneous platelet aggregation in beta-thalassemia/hemoglobin E disease: a consequence of splenectomy. ( 1298991 )
1992
20
Sickle cell-hemoglobin E disease: clinical findings and implications. ( 1960615 )
1991
21
Cerebral thrombosis in beta-thalassemia/hemoglobin E disease. ( 2339462 )
1990
22
Cardiac involvement in beta-thalassemia/hemoglobin E disease: clinical and hemodynamic findings. ( 2237594 )
1990
23
Prenatal diagnosis of the fetus at risk for beta-thalassemia/hemoglobin E disease: a report of the first case in Thailand. ( 3572289 )
1987
24
Oropharyngeal colonization with aerobic bacteria in beta-thalassemia/hemoglobin E disease. ( 3318952 )
1987
25
Hemoglobin E disease in pregnancy. ( 6151925 )
1984
26
Zinc and copper status in hemoglobin H disease and beta-thalassemia/hemoglobin E disease. ( 6817576 )
1982
27
Intracranial extramedullary hematopoiesis in beta-thalassemia/hemoglobin E disease. ( 7258183 )
1981
28
Extramedullary hematopoiesis of cranial dura mater and choroid plexus and terminal convulsions in a patient with thalassemia-hemoglobin E disease. ( 512525 )
1979
29
Hemoglobin-E, disease with mitral stenosis (a case report). ( 1032837 )
1976
30
Maternal and fetal outcome associated with hemoglobin E trait and hemoglobin E disease. ( 1079930 )
1975
31
Thalassemia-hemoglobin E disease in a Tamil christian subject. Report of a case. ( 4718417 )
1973
32
Thalassemia hemoglobin E disease. ( 5506679 )
1970
33
Pathology of abnormal hemoglobin diseases seen in Thailand. I. Pathology of beta-thalassemia hemoglobin E disease. ( 4225872 )
1967
34
A further example of thalassemia-hemoglobin E disease in Turkey. ( 4956512 )
1965
35
The hemoglobin E syndromes. II. Sickle-cell-hemoglobin E disease. ( 13792277 )
1960

Variations for Hemoglobin E Disease

ClinVar genetic disease variations for Hemoglobin E Disease:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 HBB NM_000518.4(HBB): c.79G> A (p.Glu27Lys) single nucleotide variant Pathogenic,protective rs33950507 GRCh37 Chromosome 11, 5248173: 5248173

Expression for Hemoglobin E Disease

Search GEO for disease gene expression data for Hemoglobin E Disease.

Pathways for Hemoglobin E Disease

GO Terms for Hemoglobin E Disease

Cellular components related to Hemoglobin E Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.62 F2 F5 HBA1 HBB
2 endocytic vesicle lumen GO:0071682 9.26 HBA1 HBB
3 blood microparticle GO:0072562 9.26 F2 HBA1 HBB HBE1
4 haptoglobin-hemoglobin complex GO:0031838 9.16 HBA1 HBB
5 hemoglobin complex GO:0005833 8.8 HBA1 HBB HBE1

Biological processes related to Hemoglobin E Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular oxidant detoxification GO:0098869 9.46 HBA1 HBB
2 response to hydrogen peroxide GO:0042542 9.43 HBA1 HBB
3 hemostasis GO:0007599 9.4 F2 F5
4 bicarbonate transport GO:0015701 9.37 HBA1 HBB
5 protein heterooligomerization GO:0051291 9.33 HBA1 HBB HBE1
6 positive regulation of cell death GO:0010942 9.32 HBA1 HBB
7 hydrogen peroxide catabolic process GO:0042744 9.26 HBA1 HBB
8 blood coagulation GO:0007596 9.26 F2 F5 HBB HBE1
9 oxygen transport GO:0015671 8.8 HBA1 HBB HBE1

Molecular functions related to Hemoglobin E Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.5 HBA1 HBB HBE1
2 heme binding GO:0020037 9.43 HBA1 HBB HBE1
3 peroxidase activity GO:0004601 9.37 HBA1 HBB
4 haptoglobin binding GO:0031720 9.16 HBA1 HBB
5 oxygen binding GO:0019825 9.13 HBA1 HBB HBE1
6 oxygen transporter activity GO:0005344 8.8 HBA1 HBB HBE1

Sources for Hemoglobin E Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....